1.
The Association of Body Mass Index and Body Composition with Pain, Disease Activity, Fatigue, Sleep and Anxiety in Women with Fibromyalgia.
Correa-Rodríguez, M, Mansouri-Yachou, JE, Casas-Barragán, A, Molina, F, Rueda-Medina, B, Aguilar-Ferrandiz, ME
Nutrients. 2019;11(5)
-
-
-
Free full text
Plain language summary
Fibromyalgia is a long-term condition causing symptoms such as widespread pain, fatigue, trouble sleeping and problems with memory and concentration. The purpose of this study was to examine the relationships between body mass index (BMI), body composition and fibromyalgia symptoms. 73 women with fibromyalgia and 73 healthy controls, matched on weight, were included in this cross-sectional study. Women with a higher BMI had more severe symptoms of fibromyalgia. Fat mass and visceral fat were associated with poorer quality sleep. The study’s authors concluded that promoting an ideal BMI may help to reduce some of the symptoms for women with fibromyalgia.
Abstract
The link between fibromyalgia syndrome (FMS) and obesity has not been thoroughly investigated. The purpose of this study was to examine the relationships among body mass index (BMI) and body composition parameters, including fat mass, fat mass percentage, and visceral fat, as well as FMS features, such as tender point count (TPC), pain, disease activity, fatigue, sleep quality, and anxiety, in a population of FMS women and healthy controls. A total of seventy-three women with FMS and seventy-three healthy controls, matched on weight, were included in this cross-sectional study. We used a body composition analyzer to measure fat mass, fat mass percentage, and visceral fat. Tender point count (TPC) was measured by algometry pressure. The disease severity was measured with the Fibromyalgia Impact Questionnaire (FIQ-R) and self-reported global pain was evaluated with the visual analog scale (VAS). To measure the quality of sleep, fatigue, and anxiety we used the Pittsburgh Sleep Quality Questionnaire (PSQI), the Spanish version of the multidimensional fatigue inventory (MFI), and the Beck Anxiety Inventory (BAI), respectively. Of the women in this study, 38.4% and 31.5% were overweight and obese, respectively. Significant differences in FIQ-R.1 (16.82 ± 6.86 vs. 20.66 ± 4.71, p = 0.030), FIQ-R.3 (35.20 ± 89.02 vs. 40.33 ± 5.60, p = 0.033), and FIQ-R total score (63.87 ± 19.12 vs. 75.94 ± 12.25, p = 0.017) among normal-weight and overweight FMS were observed. Linear analysis regression revealed significant associations between FIQ-R.2 (β(95% CI)= 0.336, (0.027, 0.645), p = 0.034), FIQ-R.3 (β(95% CI)= 0.235, (0.017, 0.453), p = 0.035), and FIQ-R total score (β(95% CI)= 0.110, (0.010, 0.209), p = 0.032) and BMI in FMS women after adjusting for age and menopause status. Associations between sleep latency and fat mass percentage in FMS women (β(95% CI)= 1.910, (0.078, 3.742), p = 0.041) and sleep quality and visceral fat in healthy women (β(95% CI)= 2.614, (2.192, 3.036), p = 0.008) adjusted for covariates were also reported. The higher BMI values are associated with poor FIQ-R scores and overweight and obese women with FMS have higher symptom severity. The promotion of an optimal BMI might contribute to ameliorate some of the FMS symptoms.
2.
GANODERMA LUCIDUM IMPROVES PHYSICAL FITNESS IN WOMEN WITH FIBROMYALGIA.
Collado Mateo, D, Pazzi, F, Domínguez Muñoz, FJ, Martín Martínez, JP, Olivares, PR, Gusi, N, Adsuar, JC
Nutricion hospitalaria. 2015;32(5):2126-35
-
-
-
Free full text
Plain language summary
Fibromyalgia (FM) is a chronic rheumatic disease of unknown cause which is characterized by generalized pain, stiffness, and tenderness in specific points, and is commonly associated with other symptoms including muscular stiffness, depression, non-refreshing sleep, and cognitive impairments. Ganoderma lucidum (GL, reishi) has been demonstrated to increase vital energy, stimulating the immune system, and promoting health, and to have anti-inflammatory, antioxidant, antiviral, neuroprotective, and blood pressure lowering properties. GL is rich in polyphenols and has antioxidant properties, and has been used in many Mediterranean countries. Ceratonia siliqua (CS, carob) is also rich in polyphenols and has antioxidant properties, and was used as a control in this study. The aim of this randomised, double blind, clinical trial was to evaluate the effectiveness of GL and CS to enhance physical fitness in patients with FM. Patients took either 6g GL or 6g CS daily for 6 weeks. 25 participants from the GL and 23 from the CS group completed the study. After the 6-week treatment period, a statistically significant difference in aerobic endurance was observed between both groups, with the patients in the GL group, but not those in the CS group, showing improvements. The GL group also obtained significant improvements in lower body flexibility and velocity compared with the CS group. The authors concluded that GL may be effective in improving endurance, lower body flexibility, and velocity, whilst CS seemed to be ineffective in improving physical fitness in women with FM. They discuss that no mechanism how the GL may help with physical fitness in FM patients is known and that further research is needed.
Abstract
INTRODUCTION fibromyalgia is a chronic disease characterized by generalized pain, stiffness, poor physical conditioning, non-restorative sleep and poor health-related quality of life. Ganoderma lucidum a type of mushroom that has demonstrated several benefits in different populations. Ceratonia siliqua is a natural therapy rich in antioxidants with potential benefits on health. OBJECTIVE to evaluate the effects of 6-week treatment of Ganoderma lucidum and Ceratonia siliqua on physical fitness in patients suffering from fibromyalgia. METHODS sixty-four women with fibromyalgia participated in the study. They took 6 g of Ganoderma lucidum or Ceratonia siliqua per day for 6 weeks. Different fitness tests were selected in order to evaluate functional capacity. RESULTS after the 6-week treatment period, Ganoderma lucidum significantly improved aerobic endurance, lower body flexibility, and velocity (p < .05). No significant improvement in any physical test was observed in the Ceratonia siliqua group. DISCUSSION AND CONCLUSION Ganoderma lucidum may improve physical fitness in women with fibromyalgia, whereas, Ceratonia siliqua seemed to be ineffective at increasing physical fitness. These results may indicate that Ganoderma lucidum might be a useful dietary supplement to enhance physical performance of the patients suffering from fibromyalgia. Introducción: la fibromialgia es una enfermedad crónica caracterizada por dolor crónico general, rigidez, condición física pobre, sueño no reparador y mala calidad de vida relacionada con la salud. Ganoderma lucidum es un tipo de hongo que ha demostrado tener diferentes beneficios en diversas poblaciones. La harina de algarrobo (Ceratonia siliqua) es una fuente natural de antioxidantes con potenciales beneficios para la salud. Objetivo: evaluar los efectos sobre la condición física en mujeres con fibromialgia de un tratamiento de seis semanas con Ganoderma lucidum y compararlos con los de un tratamiento con Ceratonia siliqua. Métodos: sesenta y cuatro mujeres con fibromialgia participaron en el estudio. Se hicieron dos grupos, el primer grupo tomó 6 g diarios de Ganoderma lucidum, mientras que el segundo tomó 6 g diarios de Ceratonia siliqua. Se evaluó la condición física mediante diferentes test físicos validados. Resultados: después de seis semanas de tratamiento, Ganoderma lucidum mejoró significativamente la resistencia aeróbica, la flexibilidad del miembro inferior y la velocidad (p < 0,05). Por otro lado, Ceratonia siliqua no mejoró la condición física. Discusión y conclusiones: Ganoderma lucidum puede mejorar la condición física en mujeres con fibromialgia, mientras que Ceratonia siliqua parece no ser efectivo para este propósito. Estos resultados pueden indicar que 6 g diarios de Ganoderma lucidum podrían ser un suplemento útil para mejorar la condición física en esta población.
3.
Current experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials.
Pagano, G, Aiello Talamanca, A, Castello, G, Cordero, MD, d'Ischia, M, Gadaleta, MN, Pallardó, FV, Petrović, S, Tiano, L, Zatterale, A
International journal of molecular sciences. 2014;15(11):20169-208
-
-
-
Free full text
Plain language summary
Many conditions are associated with mitochondrial dysfunction (MDF) and oxidative stress (OS). For example; some genetic diseases, aging and age-associated disorders, neurologic and psychiatric diseases, malignancies and autoimmune diseases. This review looks at the clinical trials focused on the use of mitochondrial cofactors (mitochondrial nutrients - MN) such as alpha-lipoic acid (ALA), Coenzyme Q 10 (CoQ10) and L-carnitine (CARN) which are essential in the functioning of mitochondria. Of the trials that were used in the review, 81 tested ALA, 107 tested CoQ10, 74 reports tested CARN, only 7 reports were retrieved testing double MN associations, while no report was found testing a triple MN combination. A total of 28 reports tested MN associations with “classical” antioxidants, such as antioxidant nutrients or drugs. Combinations of MN showed better outcomes than individual MN. Further studies are therefore needed.
Abstract
An extensive number of pathologies are associated with mitochondrial dysfunction (MDF) and oxidative stress (OS). Thus, mitochondrial cofactors termed "mitochondrial nutrients" (MN), such as α-lipoic acid (ALA), Coenzyme Q10 (CoQ10), and l-carnitine (CARN) (or its derivatives) have been tested in a number of clinical trials, and this review is focused on the use of MN-based clinical trials. The papers reporting on MN-based clinical trials were retrieved in MedLine up to July 2014, and evaluated for the following endpoints: (a) treated diseases; (b) dosages, number of enrolled patients and duration of treatment; (c) trial success for each MN or MN combinations as reported by authors. The reports satisfying the above endpoints included total numbers of trials and frequencies of randomized, controlled studies, i.e., 81 trials testing ALA, 107 reports testing CoQ10, and 74 reports testing CARN, while only 7 reports were retrieved testing double MN associations, while no report was found testing a triple MN combination. A total of 28 reports tested MN associations with "classical" antioxidants, such as antioxidant nutrients or drugs. Combinations of MN showed better outcomes than individual MN, suggesting forthcoming clinical studies. The criteria in study design and monitoring MN-based clinical trials are discussed.